hAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Initially discovered in Wuhan, China, SARS‑CoV‑2 spread rapidly across the globe causing the coronavirus disease 2019 (COVID-19) pandemic, leading to considerable morbidity and mortality worldwide. This prompted the development of several vaccines to help protect against the infection.

The structure of the SARS‑CoV‑2 virus comprises of many glycoproteins. An alteration in these glycoproteins such as the viral receptor binding spike (S) protein reduces the neutralizing antibody titers against the virus, increasing its virulence. Multiple variants of concern (VoCs) such as the Omicron, Delta, and Beta variants have emerged as a result of these structural alterations in SARS‑CoV‑2.

ChAdOx1 is a vaccine formulated using a non-replicating, simian-isolated adenovirus as a vector. It encodes for the non-stabilized S glycoprotein of the Beta variant. Owing to an efficacy of 74% against symptomatic cases in previous trials, it was approved for use in over 170 nations, with greater than 10.4 billion doses already administered in humans.
FOR MORE:https://dz-linkk.com/MAb68r



.